Evidence map›Paper›PMID 42298664›Full record

ReviewBMC global and public health2026

Extracting homogenous data from heterogenous diseases: RaraSwed, the Swedish national rare disease quality registry.

Sanna Mansoob, Dan Hellström, Magnus Burstedt, Malin Grände, Cecilia Gunnarsson, Stephanie Juran, Lovisa Lovmar, Katarina Sandgren, Maria Johansson Soller, Anna Wedell and 3 more

Abstract readReview
In one paragraph

Review in BMC global and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sanna MansoobDepartment of Paediatrics, Skåne University Hospital, Southern Healthcare Region, Lund, Sweden. sanna.mansoob@med.lu.se.
Dan HellströmCentre for Rare Disease South, Department of Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Southern Healthcare Region, Lund, Sweden.
Magnus BurstedtNational Committee for Knowledge-Driven Management for Rare Diseases (Nationella Programområdet Sällsynta Diagnoser) within the National System for Knowledge-Driven Management, Swedish Association of Local Authorities and Regions (SALAR), Stockholm, Sweden.
Malin GrändeRare Diseases Sweden, National Patient Advocacy Group, Riksförbundet Sällsynta diagnoser, Sundbyberg, Sweden.
Cecilia GunnarssonNational Committee for Knowledge-Driven Management for Rare Diseases (Nationella Programområdet Sällsynta Diagnoser) within the National System for Knowledge-Driven Management, Swedish Association of Local Authorities and Regions (SALAR), Stockholm, Sweden.
Stephanie JuranRare Diseases Sweden, National Patient Advocacy Group, Riksförbundet Sällsynta diagnoser, Sundbyberg, Sweden.
Lovisa LovmarNational Committee for Knowledge-Driven Management for Rare Diseases (Nationella Programområdet Sällsynta Diagnoser) within the National System for Knowledge-Driven Management, Swedish Association of Local Authorities and Regions (SALAR), Stockholm, Sweden.
Katarina SandgrenCentre for Rare Disease South, Department of Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Southern Healthcare Region, Lund, Sweden.
Maria Johansson SollerDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Anna WedellNational Committee for Knowledge-Driven Management for Rare Diseases (Nationella Programområdet Sällsynta Diagnoser) within the National System for Knowledge-Driven Management, Swedish Association of Local Authorities and Regions (SALAR), Stockholm, Sweden.
Cecilia Soussi ZanderNational Committee for Knowledge-Driven Management for Rare Diseases (Nationella Programområdet Sällsynta Diagnoser) within the National System for Knowledge-Driven Management, Swedish Association of Local Authorities and Regions (SALAR), Stockholm, Sweden.
Alexandra WennbergUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Marie Stenmark AskmalmDepartment of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Southern Healthcare Region, Lund, Sweden.ORCID http://orcid.org/0000-0003-4977-4464

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the Swedish universal healthcare system, persons living with rare diseases (PLWRD) face major challenges in receiving diagnosis and accessing care,stemming in part from heterogeneity of disease and systemic barriers to care. This contributes to health inequity and a lack of visibility for PLWRD within thehealth system. This Perspective paper provides an overview of the facilitators and challenges during the development and implementation of a national raredisease (RD) quality registry, RaraSwed. The registry collects data on RD diagnosis. Adopting a social innovation and systems thinking methodology, inaddition to governance, have proven beneficial. RaraSwed supports RD research, evidence-based RD care, and Sweden's National Quality Policy and Strategy(NQPS) for RD. Future modules on patient-reported and physician-reported data on care coordination, treatment and clinical attributes will capture the holisticpatient experience. RaraSwed may contribute to health equity for PLWRD in Sweden and in turn facilitate international RD data harmonisation.

Indexed as

Health equityHealth policyRare diseasesRegistriesSwedenUniversal health care

Identifiers

PMID42298664
PMCPMC13270570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.